ROIV
Roivant Sciences Ltd
36.60$
+0.2%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +326.6% | +85.9% | -84.5% | +0.0% | +101.5% | -16.1% | -71.3% | -27.6% | +27.2% | +26.1% | -42.8% | – | |
| – | -11.7% | +2,139.6% | -94.7% | +0.0% | +10.7% | -20.8% | -24.9% | -27.9% | +530.6% | -54.3% | -11.3% | – | |
| – | +348.6% | +59.6% | -82.7% | +0.0% | +106.5% | -15.9% | -72.6% | -27.6% | -11.0% | +69.4% | -47.4% | – | |
| – | -5.8% | +11.8% | +18.3% | -0.5% | -0.5% | +2.6% | +5.3% | +7.6% | +0.5% | +20.3% | +1.5% | – | |
| – | +44.7% | +53.9% | +2.8% | +0.0% | -30.2% | +3.9% | -8.9% | +6.8% | +22.3% | -9.6% | +4.6% | – | |
| – | -2,452.4% | – | +19.1% | +0.0% | -18.2% | +3.2% | -1.8% | +7.2% | +10.6% | +4.9% | +2.8% | – | |
| – | – | -105.2% | – | – | – | – | – | – | – | – | – | – | |
| – | +2.1% | -24.0% | +86.7% | +0.0% | – | – | – | – | – | – | – | – | |
| – | – | -103.7% | – | – | – | – | – | – | – | – | -164.9% | – | |
| – | +591.1% | -140.0% | – | +0.0% | -305.2% | – | -90.6% | +50.5% | +233.6% | +321.5% | -104.0% | – | |
| – | – | -103.0% | – | – | – | -221.9% | – | – | – | – | -162.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | -163.4% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.